-
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US87978U1088 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 28M |
---|---|
PE Ratio | None |
Target Price | 103 |
Beta | -2.28 |
Dividend Yield | None |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TPST using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025